AKTX

Akari Therapeutics Plc (AKTX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Akari Therapeutics Plc is a pre-revenue biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) utilizing its proprietary PH1 payload platform. Following the November 2024 acquisition of Peak Bio, Inc., the Company has suspended internal development of its legacy nomacopan program to prioritize its ADC pipeline, specifically the lead candidate AKTX-101.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The Company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Reduced Operating Loss: Net loss for the six months ended June 30, 2025, decreased by approximately 57% compared to the same period in 2024, driven primarily by a 74% reduction in Research and Development (R&D) expenses.
• R&D Restructuring: R&D expenses dropped from $5.6 million (YTD 2024) to $1.5 million (YTD 2025). This significant decrease is attributed to the suspension of the nomacopan HSCT-TMA clinical program and the PAS-nomacopan program, shifting focus entirely to the ADC platform.
• Non-Operating Gains: The Company recognized a $1.2 million gain on the settlement of current liabilities (vendor settlement) and a minor gain on debt extinguishment during the first half of 2025, which partially offset operating losses. No such gains were recorded in the prior year period.
• Financing Activity: The Company raised approximately $5.6 million in net proceeds from a March 2025 Private Placement. Additionally, the Company settled related-party debt through share conversions and cash payments.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year from the filing date. Cash on hand ($2.7 million) is insufficient to fund operations for the next 12 months. The Company estimates its cash runway extends only into October 2025 based on current commitments.
• Recent Financing: In August 2025 (subsequent to the period end), the Company entered into agreements for a $3.0 million private placement of promissory notes (August 2025 Notes Offering) to extend its runway. This offering includes a 20% original issuance discount and matures in one year.
• Strategic Focus: The Company is actively seeking strategic partners to advance the development of its legacy assets (nomacopan and PHP-303) externally while internally advancing the AKTX-101 ADC candidate.
• Internal Controls: The Company disclosed that its internal controls over financial reporting were not effective as of June 30, 2025, due to material weaknesses identified in the prior year. Remediation efforts are expected to begin in the third quarter of 2025.
• Legal Proceedings: The Company settled claims with former consultants for $0.4 million and resolved a lawsuit with "Sabby" Volatility Warrant Master Fund Ltd. by issuing ADSs. A former employee has filed a claim for discretionary bonuses which the Company intends to defend.

Investor Verification Checklist

• Cash Runway: Verify the closing status and terms of the August 2025 Note Offering to confirm if the October 2025 liquidity deadline is extended.
• Debt Obligations: Review the terms of the August 2025 Notes (20% OID, 1-year maturity) and existing related-party notes to assess near-term refinancing or repayment risks.
• Internal Controls: Monitor the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
• Pipeline Progress: Track pre-clinical data readouts for AKTX-101 and any announcements regarding external licensing partners for nomacopan or PHP-303.
• Dilution: Assess the impact of recent and potential future equity issuances (warrants, pre-funded warrants) on existing shareholder ownership.